Raiffeisen Bank International AG Acquires Shares of 2,477 DaVita Inc. (NYSE:DVA)

Raiffeisen Bank International AG purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,477 shares of the company's stock, valued at approximately $371,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new stake in DaVita during the 4th quarter worth approximately $41,000. Coppell Advisory Solutions LLC grew its position in shares of DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. Canada Post Corp Registered Pension Plan bought a new position in shares of DaVita in the fourth quarter worth $55,000. Venturi Wealth Management LLC raised its position in shares of DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after buying an additional 152 shares in the last quarter. Finally, Blue Trust Inc. grew its position in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after buying an additional 131 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Down 3.3%

NYSE:DVA traded down $4.86 during trading hours on Wednesday, reaching $140.91. The company's stock had a trading volume of 665,164 shares, compared to its average volume of 830,229. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market capitalization of $10.64 billion, a price-to-earnings ratio of 13.12, a PEG ratio of 1.07 and a beta of 1.14. The firm has a 50-day simple moving average of $145.81 and a 200-day simple moving average of $153.54. DaVita Inc. has a 1 year low of $131.44 and a 1 year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the previous year, the company posted $2.26 EPS. DaVita's revenue for the quarter was up 5.0% on a year-over-year basis. Research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Truist Financial decreased their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, StockNews.com raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.